Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexFemale
Age16-45
SponsorFatima Tariq

About this trial

In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.

The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.

Eligibility criteria

Qualifiers

Married or unmarried

Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).

Disqualifiers

Females already taken or taking PCOS treatment (on medical record)

Females already enrolled in another trial program

Females already taking trial drugs

Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg)

Trial design

Treatments tested in this trial

  • Myoinositol
  • Metformin

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Fatima Tariq

Lead sponsor

Combined Military Hospital Gujranwala

Sponsor institution